PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Negative EBIT growth while CRVO is at 48.36%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-35.03%
Negative operating income growth while CRVO is at 46.26%. Joel Greenblatt would press for urgent turnaround measures.
-37.55%
Negative net income growth while CRVO stands at 48.37%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-34.88%
Negative EPS growth while CRVO is at 48.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-34.88%
Negative diluted EPS growth while CRVO is at 48.50%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.03%
Share count expansion well above CRVO's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.03%
Diluted share count expanding well above CRVO's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.51%
OCF growth under 50% of CRVO's 46.74%. Michael Burry might suspect questionable revenue recognition or rising costs.
9.65%
FCF growth under 50% of CRVO's 46.74%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
10Y OCF/share CAGR at 50-75% of CRVO's 99.87%. Martin Whitman might fear a structural deficiency in operational efficiency.
54.54%
5Y OCF/share CAGR at 50-75% of CRVO's 96.56%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-31.27%
Negative 3Y OCF/share CAGR while CRVO stands at 57.11%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
85.15%
Positive 10Y CAGR while CRVO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
56.20%
5Y net income/share CAGR at 50-75% of CRVO's 97.48%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-42.46%
Negative 3Y CAGR while CRVO is 65.55%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-24.53%
Negative equity/share CAGR over 10 years while CRVO stands at 100.04%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-54.63%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.07%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
41.18%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
22.12%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.